Two women smiling

How was ENHERTU
studied?

ENHERTU was studied in a clinical trial of 101 adults who received a 5.4 mg/kg dose and:

  • Had HER2-mutant NSCLC that had spread to other parts of their body (metastatic) or could not be removed by surgery (unresectable)
  • Had their disease return after a prior treatment for lung cancer

The study included many types of adults, including those of different ages, races, genders, and smoking histories.

This study only evaluated ENHERTU. There was not a comparison of results to another treatment option for HER2-mutant metastatic NSCLC.

Two women smiling

What were the results of the ENHERTU study?

Overall response rate

More than half of people treated with ENHERTU had their tumors shrink

ENHERTU response rate ENHERTU response rate

58%

(30 of 52) of people treated with ENHERTU had their tumors shrink

Overall response rate is the proportion of patients who have a partial or complete response to therapy.

  • 56% (29 of 52) of people taking ENHERTU achieved a partial response. A partial response means there was at least 30% tumor shrinkage
  • 2% (1 of 52) of people taking ENHERTU achieved a complete response. A complete response means the tumors could not be seen on imaging tests

Median duration of response

Half of the people who responded to ENHERTU were still responding after nearly 9 months

9months

This is called median duration
of response.

ENHERTU is still being studied to confirm these results.

A median is the middle number in a set of numbers. Median duration of response is the length of time half of the people in the trial continued to respond after the first response was seen.

ENHERTU was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

Side effects icon

Understand possible side effects

Support and resources icon

Learn more about ENHERTU

HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer.